Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

On track for trial completion in the first quarter of 2022

Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients With Alcohol Use Disorder

CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, will host a conference call at 11:00 A.M. Eastern Time today, August 20, 2021 to provide a clinical update and discuss the latest business developments.

Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments

CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments.

Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments

CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on recently issued patents for the use of Adial's lead asset, AD04, for the treatment of both Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). AD04 is currently being evaluated in the Company's ONWARD trial, a Phase 3 clinical study to evaluate the efficacy, safety and tolerability of AD04 in patients with AUD, which is being conducted in seven countries.

Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04

Financing fully funds ONWARD™ Phase 3 trial until data read-out Financing fully funds ONWARD™ Phase 3 trial until data read-out

Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market

CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that an op-ed from Adial's CEO, William Stilley, has been featured on Nasdaq.com.

Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com

Data merits further testing for pain reduction as a possible alternative to opioids

Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform

CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the Company has entered into Securities Purchase Agreements (“SPAs”) for the private placement of 1,666,667 shares of common stock at a price of $3.00 per share (the “Shares”) for total proceeds of $5,000,000. The private placement was led by Bespoke Growth Partners, Inc., which subscribed for $2,500,000. Other investors include Keystone Capital Partners LLC and Richard Gilliam, founder of Cumberland Resources (collectively, “Investors”). Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as an advisor on the transaction.

Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share

Study Drug Continues to Appear to be Well-Tolerated

The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion

CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has been added to the Russell Microcap® Index. Adial's addition to the Russell Microcap Index follows the annual Russell indexes reconstitution according to a final list of additions posted on June 25, 2021. Adial's membership in the Russell Microcap® Index is effective at Nasdaq market open, today, June 28, 2021.

Adial Joins Russell Microcap® Index

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time. The FDA stated that the Company has not yet demonstrated that the product shows potential, and the agency asked for additional information regarding how AD04 might compare to other therapies.

FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder

CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has received correspondence related to its request for Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate, AD04, for the treatment of Alcohol Use Disorder (AUD) in pediatric patients and adult patients with Alcoholic Liver Disease (ALD) with select polymorphisms of the serotonin transporter and receptor genes. While AD04 is being developed and undergoing a pivotal Phase 3 trial to treat any adult with AUD with the targeted genetics, Adial believes AD04 holds the potential to effectively and safely treat AUD patients that are adolescents or have ALD.

Adial Pharmaceuticals Provides Regulatory and Development Update

MediciNova

Intec Parent

OPKO Health

vTv Therapeutics

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 10 Biotech Penny Stocks to Watch in July 2021

The Company believes the genetic companion diagnostic test for AD04 for Alcohol Use Disorder represents a multi-billion dollar potential market opportunity The Company believes the genetic companion diagnostic test for AD04 for Alcohol Use Disorder represents a multi-billion dollar potential market opportunity

Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

The stock price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) increased by over 30% pre-market. This is why it happened.

ADIL Stock Price Increases Over 30% Pre-Market: Why It Happened

CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, commends Kate Julian and The Atlantic for highlighting the major crisis facing our society in her article America Has a Drinking Problem . The article highlights the complexity of the factors driving alcohol use and its pervasiveness in human society and, particularly, in the United States.

Adial Pharmaceuticals Comments on Article in ‘The Atlantic,' Highlighting the Second Pandemic of Addiction

CHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has completed the $2,100,000 private placement of 700,001 shares of common stock at a price of $3.00 per share (the “Shares”) on June 1, 2021. The private placement investors included Bespoke Growth Partners, Inc., a company controlled by a member of management, a member of the Board of Directors of the Company, and Keystone Capital Partners, LLC. No warrants were issued and no brokers fees were incurred in this financing transaction.

Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share

CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer, and Dr. Bankole Johnson, Chief Medical Officer, have been featured on multiple news broadcasts nationwide regarding the ‘Second Pandemic of Addiction' arising from the COVID-19 pandemic.

Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder

Discusses long-term effects of COVID-19 pandemic on mental health and addiction Discusses long-term effects of COVID-19 pandemic on mental health and addiction

Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel

CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into Securities Purchase Agreements (“SPAs”) for the private placement of 700,001 shares of common stock at a price of $3.00 per share (the “Shares”), for total proceeds of $2,100,000. The private placement investors include members of Management and the Board of Directors of the Company and Keystone Capital Partners, LLC (collectively, “Investors”). No warrants or brokers fees were issued in this financing transaction.

Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 2021.

Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced the exercise of 712,500 warrants from its June 2020 financing for net proceeds to the company of $1,425,000.

Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants

CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial. ONWARD is investigating the efficacy and safety of Adial's lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes.

Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial

CHARLOTTESVILLE, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will be filing an application for “Fast Track” with the U.S. Food and Drug Administration (FDA) for its lead drug candidate, AD04, which is a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes.

Adial to File Fast Track Application for AD04 with the FDA

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that William Stilley, Chief Executive Officer of Adial Pharmaceuticals has been invited to present a Company overview at the 23rd Annual ICR Conference on Thursday, January 14, 2021 at 3:15pm-3:55pm Eastern Time. A live webcast of the Company's presentation will be available on the Investors section of the Company's website (https://www.adialpharma.com/).

News for Adial Pharmaceuticals Inc Stock (ADIL)